Poxviruses: Defining Epitope Immunodominance
痘病毒:定义表位免疫优势
基本信息
- 批准号:7698540
- 负责人:
- 金额:$ 41.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-15 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgammaglobulinemiaAntigen-Presenting CellsAntigensBacteriaBindingBiological AssayCD8B1 geneCellsCellular ImmunityDNADataDevelopmentEpitopesGenesHLA A*0201 antigenHistocompatibility Antigens Class IHumanImmune responseImmunizationIncidenceInfectionLicensingLocalizedMammalian CellMethodsPeptide LibraryPeptidesPolymerase Chain ReactionPoxviridaeProteinsRecoveryRelative (related person)Research Project GrantsScreening procedureSmallpoxSmallpox VaccineSmallpox VirusesStagingSystemT memory cellT-LymphocyteT-Lymphocyte EpitopesTransfectionTransgenic MiceVaccinationVaccinesVacciniaVaccinia virusViral ProteinsVirusbasecross reactivitycytotoxicitydesignenzyme linked immunospot assayexperimental analysisneutralizing antibodynovelpreventresponsesynthetic peptide
项目摘要
Immunization with vaccinia virus resulted in long-lasting protection against smallpox and was the
approach used to eliminate natural smallpox infections worldwide. This was accomplished without a detailed
understanding of human T cell responses to poxviruses. Due to concerns about the use of smallpox virus as
a bioweapon, smallpox vaccination is currently being reintroduced. Considering the relatively high incidence
of side effects, developing a safer, but effective vaccine is very important.
Vaccinia virus elicits strong cellular as well as humoral immune responses. Cellular immunity seems
to be more important for recovery from infection. Severe complications from vaccination were associated
with congenital or acquired T cell deficiencies, but not with congenital agammaglobulinemia. The presence
of neutralizing antibody alone did not prevent the development of progressive vaccinia if cell-mediated
immunity was defective. In order to analyze human T cell responses to licensed and experimental smallpox
vaccines at the single cell level, it is essential to identify T cell epitopes, especially immunodominant CD8 ¿ T
cell epitopes.
Vaccinia is a large virus and we hypothesize that we can develop a rapid approach to localize gene
fragments encoding human T cell epitopes and to identify them precisely using peptides using PCRgenerated
DNA fragments containing virus genes transfected into antigen presenting cells. Complementary
strategies will employ peptide libraries and studies in transgenic mice expressing common human MHC
class I molecules. The immunodominance of human T cell epitopes on vaccinia virus will be analyzed. The
results of this research project will provide valuable information relative to basic studies of human T cell
memory and data useful for the design and analyses of experimental smallpox vaccines. The methods we
will establish in this project may be applicable to other large viruses as well as bacteria for the definition of
human T cell epitopes.
通过离甲酸病毒免疫可产生对天花的持久保护,是
用于消除全球天然天花感染的方法。这是没有详细的
了解人类T细胞对痘病毒的反应。由于担心使用天花病毒作为
目前正在重新引入生物武器,天花疫苗接种。考虑到相对高事件
副作用,开发更安全但有效的疫苗非常重要。
离子病毒会引起强细胞和体液免疫调查。细胞免疫喜欢
对于从感染中恢复更为重要。疫苗接种的严重并发症是相关的
先天性或获得的T细胞缺陷,但没有先天性agammagamaglobloblobloinemia。存在
如果细胞介导
免疫力有缺陷。为了分析人类T细胞对许可和实验天花的反应
在单细胞水平上的疫苗,必须鉴定T细胞表位,尤其是免疫主导CD8€t
细胞表位。
疫苗是一种大型病毒,我们假设我们可以开发一种快速的方法来定位基因
编码人T细胞表位的片段,并使用Pcrgenated使用肽精确识别它们
含有病毒基因的DNA片段转化为抗原呈现细胞。补充
策略将在表达常见人MHC的转基因小鼠中采用肽库和研究
I类分子。将分析人类T细胞表位对离子病毒病毒的免疫优势。
该研究项目的结果将提供有关人类T细胞基础研究的宝贵信息
记忆和数据可用于实验天花疫苗的设计和分析。我们的方法
该项目将在此项目中建立可能适用于其他大型病毒以及细菌的定义
人类T细胞表位。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Masanori Terajima其他文献
Masanori Terajima的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Masanori Terajima', 18)}}的其他基金
Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination
人类 CD8 和 CD4 T 细胞对流感感染和疫苗接种的反应
- 批准号:
7701542 - 财政年份:2009
- 资助金额:
$ 41.08万 - 项目类别:
Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination
人类 CD8 和 CD4 T 细胞对流感感染和疫苗接种的反应
- 批准号:
8452138 - 财政年份:
- 资助金额:
$ 41.08万 - 项目类别:
Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination
人类 CD8 和 CD4 T 细胞对流感感染和疫苗接种的反应
- 批准号:
8053882 - 财政年份:
- 资助金额:
$ 41.08万 - 项目类别:
Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination
人类 CD8 和 CD4 T 细胞对流感感染和疫苗接种的反应
- 批准号:
8243661 - 财政年份:
- 资助金额:
$ 41.08万 - 项目类别:
Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination
人类 CD8 和 CD4 T 细胞对流感感染和疫苗接种的反应
- 批准号:
8376576 - 财政年份:
- 资助金额:
$ 41.08万 - 项目类别:
相似海外基金
Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia
X 连锁无丙种球蛋白血症患者中疫苗诱导的 SARS-CoV-2 特异性 T 细胞反应
- 批准号:
10593523 - 财政年份:2023
- 资助金额:
$ 41.08万 - 项目类别: